Cytogen unveils new oncology program

Biopharmaceutical firm Cytogen has begun a new clinical development initiative for a targeted oncology product designed to treat prostate and other cancers.

The product candidate employs DOTA-based bifunctional chelant technology to radiolabel Cytogen's proprietary monoclonal antibody to prostate-specific membrane antigen (PSMA) with a therapeutic radionuclide, according to the Princeton, NJ-based firm.

By staff writers
April 4, 2005

Related Reading

Cytogen hires medical affairs VP, December 13, 2004

Advanced Magnetics, Cytogen get FDA nod, October 20, 2004

Cytogen notches record revenues, August 6, 2004

Cytogen may join Russell 3000, June 14, 2004

Copyright © 2005

Page 1 of 461
Next Page